Antihypertensive effects of a new sustained-release formulation of nifedipine

P. K. Zachariah, Gary Lee Schwartz, S. G. Sheps, A. Schirger, C. A. Carlson, A. G. Moore

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The blood pressure response to a new sustained-release formulation of nifedipine was evaluated in an 8-week, double-blind, placebo-controlled study. Twenty-nine patients with mild essential hypertension were randomized to receive placebo (N = 9), 30 mg nifedipine (N = 10), or 60 mg nifedipine (N = 10). During treatment, 30-mg and 60-mg doses of nifedipine administered once daily decreased office blood pressures from 137/98 ± 8/2 mm Hg and 141/98 ± 15/2 mm Hg at baseline, respectively, to 126/89 ± 9/7 mm Hg and 126/86 ± 6/7 mm Hg (P<.005). Noninvasive automatic ambulatory blood pressure monitoring demonstrated a marginally significant (P<.10) reduction in the mean 24-hour blood pressure of 2/6 ± 8/8 mm Hg and 5/6 ± 9/9 mm Hg for patients taking 30 mg and 60 mg nifedipine once daily, respectively. Diastolic blood pressure load (the percentage of ambulatory diastolic blood pressure readings greater than 90 mm Hg) during 24 hours was decreased by 41% and 35%, with 30 mg and 60 mg nifedipine administered once daily, respectively. No significant dose response to nifedipine at these dose levels was observed. Although the once-daily formulation of nifedipine achieved effective control of office blood pressure, similar control was not observed in awake and 24-hour periods in all patients.

Original languageEnglish (US)
Pages (from-to)1012-1019
Number of pages8
JournalJournal of Clinical Pharmacology
Volume30
Issue number11
StatePublished - 1990

Fingerprint

Nifedipine
Antihypertensive Agents
Blood Pressure
Placebos
Ambulatory Blood Pressure Monitoring
Reading

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Zachariah, P. K., Schwartz, G. L., Sheps, S. G., Schirger, A., Carlson, C. A., & Moore, A. G. (1990). Antihypertensive effects of a new sustained-release formulation of nifedipine. Journal of Clinical Pharmacology, 30(11), 1012-1019.

Antihypertensive effects of a new sustained-release formulation of nifedipine. / Zachariah, P. K.; Schwartz, Gary Lee; Sheps, S. G.; Schirger, A.; Carlson, C. A.; Moore, A. G.

In: Journal of Clinical Pharmacology, Vol. 30, No. 11, 1990, p. 1012-1019.

Research output: Contribution to journalArticle

Zachariah, PK, Schwartz, GL, Sheps, SG, Schirger, A, Carlson, CA & Moore, AG 1990, 'Antihypertensive effects of a new sustained-release formulation of nifedipine', Journal of Clinical Pharmacology, vol. 30, no. 11, pp. 1012-1019.
Zachariah PK, Schwartz GL, Sheps SG, Schirger A, Carlson CA, Moore AG. Antihypertensive effects of a new sustained-release formulation of nifedipine. Journal of Clinical Pharmacology. 1990;30(11):1012-1019.
Zachariah, P. K. ; Schwartz, Gary Lee ; Sheps, S. G. ; Schirger, A. ; Carlson, C. A. ; Moore, A. G. / Antihypertensive effects of a new sustained-release formulation of nifedipine. In: Journal of Clinical Pharmacology. 1990 ; Vol. 30, No. 11. pp. 1012-1019.
@article{c6b68f8c02a84b31ba73d61042ed9421,
title = "Antihypertensive effects of a new sustained-release formulation of nifedipine",
abstract = "The blood pressure response to a new sustained-release formulation of nifedipine was evaluated in an 8-week, double-blind, placebo-controlled study. Twenty-nine patients with mild essential hypertension were randomized to receive placebo (N = 9), 30 mg nifedipine (N = 10), or 60 mg nifedipine (N = 10). During treatment, 30-mg and 60-mg doses of nifedipine administered once daily decreased office blood pressures from 137/98 ± 8/2 mm Hg and 141/98 ± 15/2 mm Hg at baseline, respectively, to 126/89 ± 9/7 mm Hg and 126/86 ± 6/7 mm Hg (P<.005). Noninvasive automatic ambulatory blood pressure monitoring demonstrated a marginally significant (P<.10) reduction in the mean 24-hour blood pressure of 2/6 ± 8/8 mm Hg and 5/6 ± 9/9 mm Hg for patients taking 30 mg and 60 mg nifedipine once daily, respectively. Diastolic blood pressure load (the percentage of ambulatory diastolic blood pressure readings greater than 90 mm Hg) during 24 hours was decreased by 41{\%} and 35{\%}, with 30 mg and 60 mg nifedipine administered once daily, respectively. No significant dose response to nifedipine at these dose levels was observed. Although the once-daily formulation of nifedipine achieved effective control of office blood pressure, similar control was not observed in awake and 24-hour periods in all patients.",
author = "Zachariah, {P. K.} and Schwartz, {Gary Lee} and Sheps, {S. G.} and A. Schirger and Carlson, {C. A.} and Moore, {A. G.}",
year = "1990",
language = "English (US)",
volume = "30",
pages = "1012--1019",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Antihypertensive effects of a new sustained-release formulation of nifedipine

AU - Zachariah, P. K.

AU - Schwartz, Gary Lee

AU - Sheps, S. G.

AU - Schirger, A.

AU - Carlson, C. A.

AU - Moore, A. G.

PY - 1990

Y1 - 1990

N2 - The blood pressure response to a new sustained-release formulation of nifedipine was evaluated in an 8-week, double-blind, placebo-controlled study. Twenty-nine patients with mild essential hypertension were randomized to receive placebo (N = 9), 30 mg nifedipine (N = 10), or 60 mg nifedipine (N = 10). During treatment, 30-mg and 60-mg doses of nifedipine administered once daily decreased office blood pressures from 137/98 ± 8/2 mm Hg and 141/98 ± 15/2 mm Hg at baseline, respectively, to 126/89 ± 9/7 mm Hg and 126/86 ± 6/7 mm Hg (P<.005). Noninvasive automatic ambulatory blood pressure monitoring demonstrated a marginally significant (P<.10) reduction in the mean 24-hour blood pressure of 2/6 ± 8/8 mm Hg and 5/6 ± 9/9 mm Hg for patients taking 30 mg and 60 mg nifedipine once daily, respectively. Diastolic blood pressure load (the percentage of ambulatory diastolic blood pressure readings greater than 90 mm Hg) during 24 hours was decreased by 41% and 35%, with 30 mg and 60 mg nifedipine administered once daily, respectively. No significant dose response to nifedipine at these dose levels was observed. Although the once-daily formulation of nifedipine achieved effective control of office blood pressure, similar control was not observed in awake and 24-hour periods in all patients.

AB - The blood pressure response to a new sustained-release formulation of nifedipine was evaluated in an 8-week, double-blind, placebo-controlled study. Twenty-nine patients with mild essential hypertension were randomized to receive placebo (N = 9), 30 mg nifedipine (N = 10), or 60 mg nifedipine (N = 10). During treatment, 30-mg and 60-mg doses of nifedipine administered once daily decreased office blood pressures from 137/98 ± 8/2 mm Hg and 141/98 ± 15/2 mm Hg at baseline, respectively, to 126/89 ± 9/7 mm Hg and 126/86 ± 6/7 mm Hg (P<.005). Noninvasive automatic ambulatory blood pressure monitoring demonstrated a marginally significant (P<.10) reduction in the mean 24-hour blood pressure of 2/6 ± 8/8 mm Hg and 5/6 ± 9/9 mm Hg for patients taking 30 mg and 60 mg nifedipine once daily, respectively. Diastolic blood pressure load (the percentage of ambulatory diastolic blood pressure readings greater than 90 mm Hg) during 24 hours was decreased by 41% and 35%, with 30 mg and 60 mg nifedipine administered once daily, respectively. No significant dose response to nifedipine at these dose levels was observed. Although the once-daily formulation of nifedipine achieved effective control of office blood pressure, similar control was not observed in awake and 24-hour periods in all patients.

UR - http://www.scopus.com/inward/record.url?scp=0025605048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025605048&partnerID=8YFLogxK

M3 - Article

C2 - 2243148

AN - SCOPUS:0025605048

VL - 30

SP - 1012

EP - 1019

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 11

ER -